Carlos Galdeano Cantador

Carlos Galdeano Cantador

Senior lecturer

ORCID: 0000-0003-1702-0369
Scopus Author ID: 2439870490
Researcher ID: Y-7328-2018
Knowledge area: Química Física

Research group: Biologia Computacional i Disseny de Fàrmacs

Grup d’innovació per a la millora de les competències professionals al Grau de Farmàcia

Contact Information
Department of Pharmacy and Pharmaceutical Technology and Physical Chemistry
Avd. DIAGONAL 643.
934024542
cgaldeano(a)ub.edu

Academic training

Licenciado en Farmacia
Master Experimental en Ciències Farmacèutiques
PhD en Farmacia

Projects

Una nueva plataforma híbrida para generar moleculas-prueba. Aplicación a la Fbw7 E3 ligasa . 2016 - 2018 . Ref.SAF2015-68749-R . Ministerio de Economia y Competitividad . PI: Xavier Barril Alonso
FRAGments training NETwork (FRAGNET) . 2016 - 2020 . Ref.675899 . Unió Europea . PI: Xavier Barril Alonso
A New family of sEH inhibitors for AD. CI17-00053 . 2017 - 2019 . Fundació Caixa de Pensions 'La Caixa' . PI: Merce Pallas Lliberia; Carlos Galdeano Cantador
A novel approach to enhance the therapeutic efficacy of CAR-T cells F2I-FVal_2019-013 . 2020 - 2021 . Fundació Bosch i Gimpera de la Universitat de Barcelona . PI: Carlos Galdeano Cantador
Desarrollo de nuevas aproximaciones para el descubirmeinto de moléculas prueba: aplicación a la validación terapeútica de Ligasas E3 para la degradacion de proteínas . 2019 - 2021 . Ref.RTI2018-096429-B-I00 . Ministerio de Ciencia, Innovación y Universidades . PI: Xavier Barril Alonso
A novel approach to enhance the therapeutic efficacy of CAR cells. CI20-00221 (CAIXAIMPULSE VALIDATE) . 2020 - 2022 . Ref.CI20-00221 . Fundació Caixa de Pensions 'La Caixa' . PI: Carlos Galdeano Cantador

Relevant publications

Galdeano, C.; Gadd, M.S.; Soares, P.; Scaffidi, S.; VanMolle, I.; Birced, I.;Hewitt, S.; Dias, D.M.; Ciulli. Structure-guided design and optimization of small molecules targeting the protein-protein interaction between the von hippel-Lindau (vhl) e3 ubiquitin ligase and the hypoxia inducible factor (hif) alpha subunit with in vitro nanomolar affinities. In Journal of Medicinal Chemistry. 2014 . https://doi.org/10.1021/jm5011258
Galdeano, C.; Ciulli, A. Selectivity on-target of bromodomain chemical probes by structure-guided medicinal chemistry and chemical biology. In Future Medicinal Chemistry. Volume 8. 2016
Galdeano, C. Drugging the undruggable: targeting challenging E3 ligases for personalised medicine. In Future Medicinal Chemistry. Volume 9. 2017
Soares, P.; Gadd, M.S.; Frost, J.; Galdeano, C.; Ellis, L.C.J.; Epemolu, O.; Rocha, S.; Read, K.D.; Ciulli, A. Group-based optimization of potent and cell-active inhibitors of the von Hippel-Lindau (VHL) E3 ubiquitin ligase: structure-activity relationships leading to the chemical probe (2S,4R)-1-((S)-2-(1-cyanocyclopropanecarboxamido)-3,3-dimethylbutanoyl)-4-hydroxy-N-(4-(4-methylthiazol-5-yl)benzyl)pyrrolidine-2-carboxamide (VH298). In Journal of Medicinal Chemistry. Volume 61. 2018 . https://doi.org/10.1021/acs.jmedchem.7b00675
Julianty Frost; Carles Galdeano1; Pedro Soares; Morgan S. Gadd; Katarzyna M. Grzes; Lucy Ellis; Ola Epemolu; Satoko Shimamura; Marcus Bantscheff; Paola Grandi;Kevin D. Read; Doreen A. Cantrell; Sonia Rocha; Alessio Ciulli. Potent and selective chemical probe of hypoxic signalling downstream of HIF-a hydroxylation via VHL inhibition. In Nature Communications. Volume 7. 2016
Pallàs, M.; Vázquez, S.; Sanfeliu, C.; Galdeano, C.; Griñán-Ferré, C. Soluble epoxide hydrolase inhibition to face neuroinflammation in Parkinson's disease: a new therapeutic strategy. In Biomolecules. Volume 10. Number 5. 2020 . Institutional Repository
Griñán-Ferré, C.; Codony, S.; Pujol, E.; Yang, J.; Leiva, R.; Escolano,C.; Puigoriol-Illamola, D.; Companys-Alemany, J.; Corpas, R.; Sanfeliu, C.; Pérez, B.; Loza, M.I.; Brea, J.;Morisseau, C.; Hammock, B.D.; Vázquez, S.; Pallàs, M.; Galdeano, C. Pharmacological inhibition of soluble epoxide hydrolase as a new therapy for Alzheimer's Disease. In Neurotherapeutics. 2020 . Institutional Repository
Galdeano, Carles. Drugging the undruggabl: targeting challenging E3 ligases for personalized medicine. In Future Medicinal Chemistry. Volume 9. Number 4. 2017
Julianty Frost; Carles Galdeano1; Pedro Soares; Morgan S. Gadd; Katarzyna M. Grzes; Lucy Ellis; Ola Epemolu; Satoko Shimamura; Marcus Bantscheff; Paola Grandi;Kevin D. Read; Doreen A. Cantrell; Sonia Rocha; Alessio Ciulli. Potent and selective chemical probe of hypoxic signalling downstream of HIF-a hydroxylation via VHL inhibition. In Nature Communications. Volume 7. 2016
Barril, X.; Galdeano, C. Targeted Protein Degradation Chemical Probes. In The Discovery and Utility of Chemical Probes in Target Discovery (Brennan, P.; Vazquez-Rodriguez, S.; Eds.) Series Chemical Biology No. 16. Royal Society of Chemistry. 2020

More Information: www.ub.edu/tpdlab